China’s biotech rise is fueled by its 'first to file' patent system. Companies feed newly published patents into computers to design trivially different but functionally identical molecules, effectively creating a 'shadow generic industry' that undermines IP.

Online vendors legally sell unregulated peptides by labeling them "for research only," while simultaneously providing syringes, tutorials, and marketing that normalizes human injection. This strategy exploits a regulatory loophole to create a thriving market for untested performance-enhancing drugs.

Nuanced health discussions are lost on social media algorithms that reward extreme takes. While more experts should engage, the long-term solution is to build new platforms, likely AI-driven, that prioritize substance over engagement and aren't designed to exploit our primitive impulses for profit.

In the absence of formal regulation, peptide users have created a decentralized trust system. They import substances from gray-market Chinese suppliers and then pay independent US or European labs to verify purity, creating a crowdsourced quality control process.

The danger of LLMs in research extends beyond simple hallucinations. Because they reference scientific literature—up to 50% of which may be irreproducible in life sciences—they can confidently present and build upon flawed or falsified data, creating a false sense of validity and amplifying the reproducibility crisis.

China isn't giving away its AI models out of generosity. By making them open source, it encourages widespread adoption and dependency. Once users are locked into the ecosystem, China can monetize it, introduce ads, or simply lock down future, more advanced versions, giving it significant strategic leverage.

Despite rising in global rankings, Chinese academia faces a serious credibility issue. In 2024, Chinese-authored papers saw around 3,000 retractions, compared to just 177 for U.S. authors. This is fueled by a business model of 'paper mills' that create fake academic studies.

Historically, generating a good hypothesis was the most prestigious part of science. Now, AI can produce theories at near-zero cost, overwhelming traditional validation systems like peer review. The new grand challenge is developing scalable methods to verify and filter this flood of AI-generated ideas.

In an era of scientific skepticism, companies must clearly separate general biomedical education from product-specific promotional data. Blurring these lines undermines their role as credible stewards of science, deepens the patient trust gap, and makes them appear self-serving rather than educational.